Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nashville Early Diagnosis Lung Cancer Project

Not Available
N/A
Massion, Pierre
NCT01475500
VICCTHO1078

AACR Project GENIE: Breast Cancer Sub-Project

Not Available
N/A
Park, Ben
VICCBRE1694

Bronchoscopy with Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell or Small Cell Lung Cancer

This pilot clinical trial studies how well bronchoscopy with bronchoalveolar lavage works in identifying biomarkers of response to immune checkpoint inhibitors in patients with non-small cell or small cell lung cancer. Bronchoscopy uses a thin, tube-like instrument inserted through the nose or mouth to view the inside of the trachea, air passages, and lungs. Bronchoalveolar lavage washes out the bronchi and alveoli by flushing with a fluid. Bronchoscopy with bronchoalveolar lavage may make it easier to help determine biomarkers that are more present in some cancers than others that will help determine which individuals have a greater or lesser chance of benefiting from immunotherapy.
Not Available
N/A
Maldonado, Fabien
NCT02937402
VICCTHO16108

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients with Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

This phase I / II trial studies the side effects of fludarabine phosphate, cyclophosphamide and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the patient’s body to accept the incoming donor’s bone marrow and decrease the risk that the patient's immune system will reject the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can attack the body's normal cells called graft versus host disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the transplant may help decrease this from happening.
Not Available
N/A
Connelly, James
NCT00358657
VICCNCPED1414

Detection of Cervical Precancers Using Near Infrared Raman Spectroscopy: A Pilot In Vivo Study

Not Available
N/A
Mahadeven-Jansen, Anita
VICCGYN99011

Noninvasive Detection of Skin Cancers Using Optical Spectroscopy; A Pilot In-Vivo Study

Not Available
N/A
Mahadeven-Jansen, Anita
VICCDERM99013

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-803 / M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin, gemcitabine, and cisplatin to determine the safety and maximum tolerated dose.
Not Available
I
Not Available
NCT02278250
VICCPHI14126

18F-FSPG PET / CT in Imaging Patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

This phase II trial compares fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) / computed tomography (CT) to the standard of care fludeoxyglucose F-18 (18F-FDG) PET / CT in imaging patients with newly diagnosed lung cancer or indeterminate pulmonary nodules. PET / CT uses a radioactive glutamate (one of the common building blocks of protein) called 18F-FSPG which may be able to recognize differences between tumor and healthy tissue. Since tumor cells are growing, they need to make protein, and other building blocks, for cell growth that are made from glutamate and other molecules. PET / CT using a radioactive glutamate may be a more effective method of diagnosing lung cancer than the standard PET / CT using a radioactive glucose (sugar), such as 18F-FDG.
Not Available
II
Massion, Pierre
NCT02448225
VICCTHO1524

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Not Available
III
York, Sally
NCT02193282
ECOGTHOA081105

Gabapentin Compared to Usual Care in Preventing Mucositis in Participants with Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

This randomized phase III trial studies how well gabapentin and usual care work compared to usual care alone in preventing inflammation of the mucous membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and neck may cause a burn involving the inside of the mouth, throat, and nasal passages, resulting in pain. Gabapentin may help prevent (or minimize) radiation-induced mucositis in patients with head and neck cancer.
Not Available
III
Smith, Derek
NCT02480114
VICCHN1541

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: